The Effect of Beta Interferon on the Expression of miR-145 in Patients with Multiple Sclerosis

Document Type : Original Article(s)

Authors

1 MSc Student, Pediatric Inherited Diseases Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease AND Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Associate Professor, Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Associate Professor, Pediatric Inherited Diseases Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease AND Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: microRNAs are non-coding RNAs that modulate different types of cellular processes like differentiation and cell death. Hitherto several studies have been done to determine the expression profile of microRNAs in patients with multiple sclerosis (MS) to obtain appropriate biomarkers. In previous studies, it was found that miR-145 was over-expressed. This up-regulation was in patients who did not start taking medicine. Therefore, in this study we assessed the effect of beta interferon on the expression of this microRNA in patients with multiple sclerosis.Methods: We evaluated the expression pattern of miR-145 in 15 patients who did not start taking medicine and called treatment naive, in 15 patients who were under treatment and also 15 healthy people using real-time polymerase chain reaction method.Findings: The expression level of miR-145 in treatment naive patients was 3.9 fold of healthy people (P = 0.005), whereas expression level of this microRNA between healthy people and under treatment patients was not significantly different.Conclusion: Down-regulation of miR-145 in under-treatment patients to the extent of healthy people suggests that probably, this microRNA could be used as predictive biomarker.

Keywords

References

  1. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359(9313): 1221-31.
  2. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128(Pt 11): 2705-12.
  3. Ameres SL, Zamore PD. Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol 2013; 14(8): 475-88.
  4. Siomi H, Siomi MC. Posttranscriptional regulation of microRNA biogenesis in animals. Mol Cell 2010; 38(3): 323-32.
  5. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 2006; 103(33): 12481-6.
  6. Yu D, Tan AH, Hu X, Athanasopoulos V, Simpson N, Silva DG, et al. Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA. Nature 2007; 450(7167): 299-303.
  7. Gandhi R. miRNA in multiple sclerosis: search for novel biomarkers. Mult Scler 2015; 21(9): 1095-103.
  8. Sondergaard HB, Hesse D, Krakauer M, Sorensen PS, Sellebjerg F. Differential microRNA expression in blood in multiple sclerosis. Mult Scler 2013; 19(14): 1849-57.
  9. Gandhi R, Healy B, Gholipour T, Egorova S, Musallam A, Hussain MS, et al. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol 2013; 73(6): 729-40.
  10. Sturzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, Mattar P, et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 2003; 126(Pt 6): 1419-29.
  11. Jin XF, Wu N, Wang L, Li J. Circulating microRNAs: a novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases. Cell Mol Neurobiol 2013; 33(5): 601-13.
  12. Sievers C, Meira M, Hoffmann F, Fontoura P, Kappos L, Lindberg RL. Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects. Clin Immunol 2012; 144(1): 70-9.
  13. Munoz-Culla M, Irizar H, Castillo-Trivino T, Saenz-Cuesta M, Sepulveda L, Lopetegi I, et al. Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. Mult Scler 2014; 20(14): 1851-9.
  14. Ingwersen J, Menge T, Wingerath B, Kaya D, Graf J, Prozorovski T, et al. Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b. Ann Clin Transl Neurol 2015; 2(1): 43-55.
  15. Meira M, Sievers C, Hoffmann F, Rasenack M, Kuhle J, Derfuss T, et al. Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis. J Immunol Res 2014; 2014: 897249.
  16. Singh J, Deshpande M, Suhail H, Rattan R, Giri S. Targeted stage-specific inflammatory microrna profiling in urine during disease progression in experimental autoimmune encephalomyelitis: Markers of disease progression and drug response. J Neuroimmune Pharmacol 2016; 11(1): 84-97.
  17. Waschbisch A, Atiya M, Linker RA, Potapov S, Schwab S, Derfuss T. Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis. PLoS One 2011; 6(9): e24604.
  18. Keller A, Leidinger P, Lange J, Borries A, Schroers H, Scheffler M, et al. Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PLoS One 2009; 4(10): e7440.
  19. Hecker M, Thamilarasan M, Koczan D, Schroder I, Flechtner K, Freiesleben S, et al. MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients. Int J Mol Sci 2013; 14(8): 16087-110.
  20. De Felice B, Mondola P, Sasso A, Orefice G, Bresciamorra V, Vacca G, et al. Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-beta. BMC Med Genomics 2014; 7: 26.
Journal of Isfahan Medical School
Volume 34, Issue 396 - Serial Number 396
July and August 2016
Pages 1013-1018

Files

History

  • Receive Date: 31 August 2016
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics